In what shakes out to be the largest follow-on stock offering in biopharma history, Revolution Medicines Inc., an oncology company that was the subject of buyout rumors earlier this year, priced 10.56 million shares to raise $1.5 billion, just two days after wowing investors with top-line phase III data of its RAS inhibitor daraxonrasib in patients with metastatic pancreatic ductal adenocarcinoma. The shares (NASDAQ:RVMD) were offered at $142 each, and were trading midday April 15 at $149, up $1.99. In addition to the stock sale, the company priced $500 million in convertible senior notes due 2033. According to BioWorld data, the stock sale falls in fourth place behind three big pharma companies, all of which were divesting ownership stakes in other companies, and were not offering new shares, as is the case with traditional follow-on offerings. That puts Revolution Medicines in the top spot, ahead of Vaxcyte Inc. and Moderna Inc., which raised $1.49 billion and $1.34 billion in 2024 and 2020 through follow-ons, respectively.

Pricing standoff leaves Australian patients in limbo

A pricing standoff between Pfizer Inc. and the Australian government has left women with advanced breast cancer facing tens of thousands of dollars in out-of-pocket costs, underscoring a growing global trend in which access to life-extending drugs is increasingly being shaped by pricing negotiations rather than clinical merit. At the center of the dispute is Tukysa (tucatinib), a targeted therapy for HER2-positive metastatic breast cancer in patients with brain metastases. Despite receiving a positive recommendation from Australia’s Pharmaceutical Benefits Advisory Committee in November 2025, the drug is still not listed on the Pharmaceutical Benefits Scheme after Pfizer walked away from pricing negotiations.

Alivecor receives CE mark for AI-powered, portable ECG system

Alivecor Inc. has secured CE marking for its Kardia 12L electrocardiogram (ECG) system which is powered by its KAI 12L AI technology and can detect life-threatening cardiac conditions. Kardia 12L is a portable, AI-guided, 12-lead ECG solution that delivers measurements and interpretations similar to standard 12-lead ECG solutions, right at the point of care. The company said the simplified design will enable faster acquisition of complete ECG data leading to better patient outcomes.

Abbott’s Exact acquisition drives med-tech M&A to $23.7B in March

Med-tech M&A activity surged in March 2026, with deal value reaching $23.66 billion, the highest monthly total in several years and a sharp increase from $17.53 billion in February and $1.69 billion in January. The bulk of the month’s M&A value came from Abbott Laboratories’ $21 billion acquisition of Exact Sciences Corp., marking its entry into the cancer screening market.

Newco news: Remedy pushes ‘cell-free’ secretome therapy for IPF into phase I

“Single drugs targeting single biological pathways are insufficient for complex diseases,” Remedy Cell Ltd. CEO Ayelet Dilion Mashiah told BioWorld. Remedy is taking a secretome-based approach to treat lung disorders, having moved its lead asset, RC-0315, into a first-in-human clinical trial for idiopathic pulmonary fibrosis (IPF) in January. Secretomes refer to the collection of bioactive molecules secreted by cells in the extracellular space, including proteins, enzymes, growth factors and extracellular vesicles such as exosomes.

NLRP3 inhibitors gaining traction in the wake of Lilly’s Ventyx takeover

NLR family pyrin domain containing 3 (NLRP3) inhibitors have occupied the energies of various drug developers. A paper published March 26 in Nature explored mechanisms linked to the NLRP3 inflammasome, after Eli Lilly and Co.’s buyout of Ventyx Biosciences Inc. for $1.2 billion at the start of the year cranked up interest. Ventyx is considered a strong player in the space along with Neumora Therapeutics Inc.

Flow of Trump EOs slowing way down

Despite key vacancies and ongoing staffing issues at the U.S. CDC, FDA and NIH, some of the regulatory churn that roiled those agencies in the first year of the second Trump administration is calming a bit, at least in terms of the number of executive orders (EOs) coming out of the Oval Office. President Donald Trump issued 28 EOs in the first quarter of this year, that’s two more than he signed on his first day in office and 26% of the 108 he issued in the full first quarter of 2025.

Also in the news

4D Path, Actuate, Adagene, Adcendo, Advanced Bionics, Alamar, Alkermes, Antiva, Asgard, Bioaffinity, Biotronik, Bostongene, Clearmind, Crossbridge, Daiichi, Eli Lilly, Galera, Grace, Harbinger, Harmony, Holling, Immunogenesis, Inspira, Kailera, Kashiv, Kazia, Kelun-Biotech, Kiora, Kivu, Laigo, Ligand, Neurocrine, Novo Nordisk, Nxera, Obsidian, Panntherapi, Parabilis, Penumbra, Praxis, Protaryx, Radical Catheter, Renaissance, Renovorx, Senhwa, Sirtex, Spiral, Tempest, Toby, Travere, Valanx, Valo, Vasa, Vectus, Xortx